The AI-driven genomics company Genomenon has announced that it will work with COMBINEDBrain, SynGAP Research Fund and SLC-6A1 Connect. COMBINEDBrain is a 501(c)(3) company focused on developing new treatments for neurodevelopmental disorders. COMBINEDBrain partners with more than 30 neurodevelopmental rare disease foundations, including SynGAP Research Fund and SLC6A1 Connect. “Our collaboration with Genomenon represents a big step toward finding…